Beijing Sun Novo Pharmaceutical Research Co Ltd Total Liabilities
Beijing Sun Novo Pharmaceutical Research Co Ltd total liabilities. Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has total liabilities worth CN¥1.03 Billion CNY (≈ $151.08 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688621 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Total liabilities of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luye Pharma Group Ltd
F:LUP
|
Germany | €14.47 Billion |
|
I.E.S Holdings Ltd
TA:IES
|
Israel | ILA367.96 Million |
|
Blacksky Technology Inc
NYSE:BKSY
|
USA | $305.49 Million |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
China | CN¥719.08 Million |
|
Tongyang Life
KO:082640
|
Korea | ₩32.95 Trillion |
|
Addnode Group AB (publ)
ST:ANOD-B
|
Sweden | Skr6.64 Billion |
|
Bank Sinarmas Tbk
JK:BSIM
|
Indonesia | Rp40.60 Trillion |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
USA | $7.55 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Beijing Sun Novo Pharmaceutical Research Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Beijing Sun Novo Pharmaceutical Research asset portfolio.
Liquidity & Leverage Metrics
Beijing Sun Novo Pharmaceutical Research Co Ltd Total Liabilities Ratios Explained
Beijing Sun Novo Pharmaceutical Research Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Sun Novo Pharmaceutical Research Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
The table below shows the annual total liabilities of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.05 Billion ≈ $153.84 Million |
+18.84% |
| 2024-12-31 | CN¥884.65 Million ≈ $129.45 Million |
+9.79% |
| 2023-12-31 | CN¥805.76 Million ≈ $117.91 Million |
+45.22% |
| 2022-12-31 | CN¥554.86 Million ≈ $81.19 Million |
+17.30% |
| 2021-12-31 | CN¥473.01 Million ≈ $69.22 Million |
+146.44% |
| 2020-12-31 | CN¥191.94 Million ≈ $28.09 Million |
+15.10% |
| 2019-12-31 | CN¥166.76 Million ≈ $24.40 Million |
+30.61% |
| 2018-12-31 | CN¥127.68 Million ≈ $18.68 Million |
+66.20% |
| 2017-12-31 | CN¥76.82 Million ≈ $11.24 Million |
-- |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platfo… Read more